[EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].

Abstract

INTRODUCTION:

Bullous pemphigoid is a common autoimmune blistering disorder, characterized by sub-epidermal bullae formation, that tends to affect older patients. We report on a 78 -year-old male patient suffering from bullous pemphigoid, whose disease persisted despite treatment with potent topical corticosteroids, systemic tetracyclines, prednisone and azathioprine. Recently, omalizumab was reported to be effective in several patients with resistant bullous pemphigoid. Omalizumab is a monoclonal antibody against IgE, approved for the treatment of asthma and chronic urticaria and known for its excellent safety profile. The patient was treated accordingly with omalizumab for his bullous pemphigoid with dramatic and rapid regression of his disease.

• Authors: Michal Neumark, Yuval Tal, Abraham Zlotogorski, Vered Molho-Pessach
• Journal: Harefuah (Harefuah) Vol. 159 Issue 1 Pg. 29-30 (Jan 2020) ISSN: 0017-7768 [Print] Israel
• PMID: 31930804 (Publication Type: Journal Article)

Chemical References

• Anti-Allergic Agents
• Antibodies, Monoclonal
• Omalizumab
• Prednisone

Topics

• Aged
• Anti-Allergic Agents (therapeutic use)
• Antibodies, Monoclonal
• Autoimmune Diseases
• Humans
• Male
• Omalizumab (therapeutic use)
• Pemphigoid, Bullous (drug therapy)
• Prednisone